• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Issues that matter
    • COVID-19 in India
    • Inadequate safe drinking water
    • Poor sanitation
    • Environmental health
    • Infectious disease
      • Hepatitis C
    • Noncommunicable Diseases (NCDs)
    • Malnutrition
    • High infant mortality
    • Mental health
    • Sex and gender discrimination
  • Special Focus
    • Interviews
      • Exclusive Interviews
      • Readers Interviews
    • Vaccine Hesitancy
  • News
  • PandemiCast
  • Partner’s Press Office

Health Issues India

Health issues in India

  • Home
  • About Us
  • Editorial Team
  • Subscribe
  • Contribute
  • Sponsor
  • Contact Us
You are here: Home / Featured / Considerable increase in COVID-19 deaths in China; The latest health stories from around the world

Considerable increase in COVID-19 deaths in China; The latest health stories from around the world

December 28, 2022 By Lalita Panicker Leave a Comment

Confirmed cases of COVID-19 concept. a covid-19 blood test tube with result of positive on yellow background the X has clipping path and can be removed. COVID-19 testing concept. Antibody tests concept. Image credit: 罗 宏志 / 123rf. COVID-19 cases now number at one million: concept. Testing illustration. Symptomatic COVID-19 illustration. Cases of COVID-19 in India concept. COVID-19 clusters concept.. new covid-19 variant mutant strain long covid. COVID-19 cases concept. Even after recovery from COVID-19, long-COVID symptoms may persist. Image credit: 罗 宏志 / 123rf. B.1.617 concept. black fungus. Delta plus variant concern. Delta variant concept. Excess mortality illustration. Fresh COVID-19 cases illustration.
Image credit: 罗 宏志 / 123rf

More than 5,000 people are probably dying each day from COVID-19 in China, health data firm Airfinity estimated, offering a dramatic contrast to official data from Beijing on the country’s current outbreak.www.medscape.com/viewarticle/986013?src=wnl_edit_tpal&uac=398271FG&impID=5026929&faf=1

The UK-based firm said it had used modelling based on regional Chinese data to produce figures that also put current daily infections in the country at above a million.

Its estimates were “in stark contrast to the official data which is reporting 1,800 cases and only seven official deaths over the past week,” it said in a statement.

China’s National Health Commission (NHC) did not immediately respond to a request from Reuters for comment. On Thursday it reported no new COVID-19 deaths and 2,966 new local symptomatic cases for Dec. 21.

A senior World Health Organization official said on Wednesday that China might be struggling to keep a tally of COVID infections as it experiences a big spike in cases.

An abrupt U-turn by China on its previous zero-COVID policy following protests has raised global concerns of widespread infections among a vulnerable, under-vaccinated population. It has stopped mass testing and no longer reports asymptomatic cases.

Airfinity said its mortality risk analysis suggested between 1.3 to 2.1 million people could die in China’s current COVID outbreak. Analyses by other modelling groups have also predicted as many as 2.1 million deaths.

Airfinity estimates the wave could have two peaks at 3.7 million a day in mid-January in regions where cases are currently rising and 4.2 million a day in March in other provinces.

Cases were currently rising fastest in Beijing and the southern province of Guangdong, said the firm.

According to its website, in 2020 it built “the world’s first dedicated COVID-19 health analytics and intelligence platform which is now the trusted source of decision makers and media globally.”

This week, a leading Chinese medical expert said only deaths caused by pneumonia and respiratory failure after contracting COVID will be classified as having been caused by the coronavirus.

Half a million people a day are being infected with COVID-19 in a single Chinese city, a senior health official Bo Tao has said, in a rare and quickly censored acknowledgment that the country’s wave of infections is not being reflected in official statistics. www.theguardian.com/world/2022/dec/24/chinese-city-seeing-half-a-million-covid-cases-a-day-local-health-chief?

A news outlet operated by the ruling Communist party in Qingdao reported the municipal health chief as saying that the eastern city was seeing “between 490,000 and 530,000” new COVID cases a day.

The coastal city of about 10 million people was “in a period of rapid transmission ahead of an approaching peak”, Bo Tao reportedly said on Friday, adding that the infection rate would accelerate by another 10% over the weekend.

The report was shared by several other news outlets but appeared to have been edited by Saturday morning to remove the case figures.

China’s National Health Commission said that just 4,103 new infections were recorded across the entire country on Friday, with no new deaths. In Shandong, the province where Qingdao is located, authorities officially logged just 31 new domestic cases.

China this month rapidly dismantled key pillars of its zero-Covid strategy, doing away with snap lockdowns, lengthy quarantines and travel curbs in a quick reversal of its hallmark containment strategy.

Cities across the country have struggled to cope as surging infections have emptied pharmacy shelves, filled hospital wards and appeared to cause backlogs at crematoriums and funeral homes.

But the end of strict testing mandates has made caseloads virtually impossible to track, while authorities have narrowed the medical definition of a Covid death in a move experts have said would suppress the number of fatalities attributable to the virus.

Most government-run publications have downplayed the severity of the country’s exit wave, instead depicting the policy reversal as logical and controlled.

But some outlets have hinted at shortages of medicine and hospitals under strain, though estimates of actual case numbers remain rare.

The government of eastern Jiangxi province said on Friday that 80% of its population – equivalent to about 36 million people – would be infected by March.

China is expecting a peak in COVID-19 infections within a week, a health official said, with authorities predicting extra strain on the country’s health system even as they downplay the disease’s severity and continue to report no new deaths. www.medscape.com/viewarticle/986073?src=wnl_edit_tpal&uac=398271FG&impID=5026929&faf=1

In the face of a surging outbreak and widespread protests against its “zero-COVID” regime of lockdowns and testing, China began dismantling it this month, becoming the last major country to move towards living with the virus.

Its containment measures had slowed the $17-trillion economy to its lowest growth rate in nearly half a century, jamming global supply chains and trade.

Zhang Wenhong, director of the National Centre for Infectious Diseases, was quoted in Shanghai government-backed news outlet The Paper on Thursday as saying China “is expected to reach the peak of infections within a week.”

“The peak infection will also increase the rate of severe disease, which will have a certain impact on our entire medical resources,” he said, adding the wave will last another one or two months after that.

“We must be mentally prepared that infection is inevitable.”

Chinese state media Qingdao Daily late on Friday cited a health official in eastern city of Qingdao as saying coronavirus was in rapid transmission stage in the city with 490,000-530,000 new daily infections, which was set to increase at a rate of 10% in the next couple of days.

Nearly 37 million people in China may have been infected with COVID-19 on a single day this week, Bloomberg News reported on Friday, citing estimates from the government’s top health authority.

A Shanghai hospital has estimated half of the commercial hub’s 25 million people would get infected by the end of next week. Experts say China could face more than a million COVID deaths next year.

Cities, meanwhile, continue to ease rules.

More than a dozen global health experts, epidemiologists, residents and political analysts interviewed by Reuters identified the failure to vaccinate the elderly and communicate an exit strategy to the public, as well as excessive focus on eliminating the virus, as causes of the strain on China’s medical infrastructure.

A drive to vaccinate the elderly that began three weeks ago has yet to bear fruit. China’s overall vaccination rate is above 90% but the rate for adults who have had booster shots drops to 57.9%, and to 42.3% for people aged 80 and older, according to government data.

China spent big on quarantine and testing facilities over the past three years rather than bolstering hospitals and clinics and training medical staff, these people said.

The country has nine domestically developed COVID shots approved for use, all seen as less effective than Western-made vaccines that use the new mRNA technology.

The World Health Organization has received no data from China on new COVID hospitalizations since Beijing lifted its zero-COVID policy. The WHO has said gaps in data might be due to Chinese authorities simply struggling to tally cases.

////

www.reuters.com/business/healthcare-pharmaceuticals/biontech-initiates-clinical-trial-mrna-based-malaria-vaccine-candidate-2022-12-23/

BioNTech (22UAy.DE) on Friday initiated an early-stage study to evaluate its experimental malaria vaccine in humans, the German drugmaker said.

The Phase 1 trial is expected to enrol 60 volunteers in the United States with no history of malaria to assess the vaccine candidate at three-dose levels.

Known as BNT165b1, it is the first vaccine candidate from BioNTech’s malaria project, which will also establish vaccine production in Africa.

The effort is one of several focused on addressing the mosquito-borne disease that kills over 600,000 each year, most of them children in Africa. The complicated structure and lifecycle of the malaria parasite has long stymied efforts to develop vaccines.

After decades of work, the only approved malaria vaccine, Mosquirix, made by British drugmaker GSK (GSK.L), was this year endorsed by the WHO, but a lack of funding and commercial potential has thwarted GSK’s capacity to produce as many doses as needed.

Another keenly-watched effort is a malaria vaccine from Oxford University. Mid-stage trial data was published in September.

No direct comparisons have been made, but some scientists suggest the Oxford shot is a step forward from Mosquirix and provides longer immunity.

BioNTech’s malaria vaccine effort is based on its mRNA technology, which was employed during the pandemic to quickly develop COVID-19 vaccines, by prompting the human body to make a protein that is part of the pathogen, triggering an immune response.

///

 Lalita Panicker is Consulting Editor, Views and Editor, Insight, Hindustan Times, New Delhi

Filed Under: Featured, Featured Story, Infectious diseases, International, News, Newsletter Tagged With: BioNTech, COVID-19, Malaria

Reader Interactions

Leave a Reply Cancel reply

You must be logged in to post a comment.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Primary Sidebar

Articles

  • Renewed fears of a bird flu pandemic; The latest health stories from around the world
  • More oversight needed for “gain of function” research says expert panel; The latest health stories from around the world
  • Marion Biotech to be investigated by Indian drug regulator
  • Sesame to be added to list of major food allergens
  • Approval of Alzheimer’s drug “rife with irregularities”

Footer

Archives

Issues that matter

  • Environmental health
  • Inadequate safe drinking water
  • Poor sanitation
  • Infectious disease
  • Noncommunicable Diseases (NCDs)
  • Malnutrition
  • High infant mortality

Categories

Copyright © 2023 · News Pro On Genesis Framework · WordPress · Log in

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies. However you may visit Cookie Settings to provide a controlled consent.
Cookie settingsACCEPTACCEPT ALL
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.
CookieDurationDescription
cookielawinfo-checkbox-analytics11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional11 monthsThe cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance11 monthsThis cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
viewed_cookie_policy11 monthsThe cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
Functional
Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.
Performance
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
Analytics
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.
Advertisement
Advertisement cookies are used to provide visitors with relevant ads and marketing campaigns. These cookies track visitors across websites and collect information to provide customized ads.
Others
Other uncategorized cookies are those that are being analyzed and have not been classified into a category as yet.